Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of norursodeoxycholic acid in NASH
MOH_2022-12-27_012214Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of norursodeoxycholic acid in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Dr. Falk Pharma GmbH. Started Dec 2022; status: completed.
02
Drugs
norursodeoxycholic acid
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on MOH_2022-12-27_012214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-27_012214.